CEACAM5 and familial pancreatic carcinoma: While CEA remains a valuable tumor marker in selected oncology settings, particularly in the follow-up of colorectal, gastric, and pancreatic cancers, its utility is limited in asymptomatic individuals due to its low specificity [1,2].